News and Resources

  • Event

    Image-guided cancer care: Why interventional oncology deserves greater consideration

    09 December 2026, Online

    Cancer treatment is no longer limited to surgery, radiotherapy and systemic therapies. Advances in medical imaging have opened the door to increasingly precise, minimally invasive approaches that can expand treatment options and improve the way cancer is managed.

     

    Yet, despite these advances, interventional oncology (IO) is too often under-represented in multidisciplinary team discussions, clinical guidelines and cancer care pathways. Ensuring that patients can benefit from the full range of available treatment options requires closer collaboration between the different specialists involved in cancer care.

     

    To address this challenge, the European Cancer Organisation (ECO), through its Young Cancer Professionals (YCP) group, is joining forces with the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) for a timely discussion on the role of image-guided therapies in modern oncology.

     

    Join us on Wednesday, 9 December, from 16:00 to 17:30 CET, and discover why interventional oncology deserves a stronger place in the European cancer conversation. Registration is now open.

    Read more
  • Event

    European Conference on Inter-Speciality Cancer Training and Care

    20 November 2026, The Hotel Brussels & Online

    Advancing Collaboration, Skills and Person-Centred Care through INTERACT-EUROPE 100

    INTERACT_November_conference_18.png

    Bringing together Europe’s oncology community at a pivotal moment, this conference will showcase the achievements of INTERACT-EUROPE 100 while charting the next phase of inter-speciality cancer training across Europe. It offers a unique opportunity to transform the programme’s success into lasting, system-wide adoption, ultimately advancing cancer care and outcomes for people across Europe.

    Read more
  • Event

    Quality of Life and Cancer Policy Forum: Bridging Research, Practice and Policy-Making

    20 November 2026, The Hotel Brussels

    Quality of life is a key priority for anyone affected by cancer, but it remains insufficiently addressed in cancer research, care and policy.

     

    On 20 November, the Quality of Life and Cancer Policy Forum will explore lessons from nine innovative projects and how cancer systems can be redesigned towards patient-centred care.

     

    Taking place a day after the European Cancer Summit 2026 – and at the same venue – this high-level, implementation-focused event will bring together patient representatives, researchers, healthcare professionals, health system managers and policymakers to learn about the latest EU-supported initiatives and get empowered to drive meaningful change.

     

    This event will feature:

    • the EUonQoL project, developing a patient-centred unified tool for the assessment of quality of life among cancer patients and survivors – serving as its final policy event
    • the projects of the Quality of Life - Patient-Centred Care Cluster of the EU Mission on Cancer – serving as their multi-stakeholder meeting

     

    Read more
  • Event

    European Cancer Summit 2026

    18 - 19 November 2026, Brussels & online

    Strengthening Cancer Care: Securing a Healthy, Equitable, Resilient and Competitive Europe

     

    Amid political instability, economic pressure, and the risk of escalating conflict, discussions around Europe’s next multiannual budget are intensifying in Brussels and in capitals across the EU.  

     

    In this environment, addressing the growing burden of cancer is essential. This unrelenting disease is not only a public health priority, but a strategic investment in Europe’s resilience, social cohesion and long‑term competitiveness.

     

    As Europe defines its political priorities for the decade ahead, health and cancer must be embedded at the heart of future investments. At this critical moment, the cancer community must champion a vision for a resilient, equitable and innovative Europe.

     

    The European Cancer Summit 2026 will take place in Brussels & online on 18-19 November, followed by EU-funded project events on 20 November.

    Read more
  • Publication

    From data to action: New ECO report calls for stronger use of patient-reported outcomes in European cancer care

    November 2026

     

    Patient-Reported Outcome Measures (PROMs) are increasingly recognised as essential tools for understanding how people experience cancer and its treatment. Yet across Europe, significant challenges remain in ensuring that this information is systematically collected, interpreted and used to improve care and inform decision-making.

    The European Cancer Organisation has published a new Policy Action Report, Taking a global lead on patient-reported outcome measures. What's holding Europe back?, setting out practical recommendations to strengthen the implementation of PROMs across clinical practice, clinical trials and health policy.

    Read more
  • Publication

    Closing the Response Gap for People Living with Metastatic Cancer

    November 2026

     

    A growing number of people across Europe are living longer – often years longer – with metastatic cancer. Yet healthcare systems and public policies have not kept pace with their changing needs, creating a growing gap between advances in treatment and the care and support available to patients.

    Read more
  • Publication

    Sustaining Our Oncology Professions: Meeting Their Needs

    October 2026

     

    Europe's cancer workforce is under growing pressure. As cancer care becomes increasingly complex and demand continues to rise, ensuring that healthcare professionals have the recognition, training and support they need is essential to delivering high-quality care to patients across Europe.

    Read more
  • community-voices

    Image-Guided Cancer Care: The Value of Interventional Oncology

    October 2026

    Franco_Orsi.jpeg

     

    By Orsi-Pereira, CIRSE

    Imaging has transformed modern cancer care. Morphological, functional and molecular imaging, including MRI and PET/CT, can detect and characterise tumours, define their relationship with surrounding organs and assess treatment effects.

    Interventional Oncology takes this progress one step further. It uses imaging not only to diagnose a tumour, but also to guide and monitor its treatment directly. The images become a real-time map for targeted, minimally invasive therapies adapted to the tumour and the individual patient: personalised medicine in practice.

    During treatment, imaging allows the operator to monitor the instruments, the therapy as it is delivered and nearby healthy tissues. Imaging becomes part of the treatment, helping to target the tumour while preserving healthy tissue.

    Interventional Oncology includes image-guided procedures such as tumour ablation, embolisation, intra-arterial therapies and supportive interventions used to control symptoms or manage complications caused by cancer and its treatments.

    These therapies do not compete with surgery or systemic treatment. Depending on the clinical situation, they may complement or be combined with these approaches, or may be offered instead of surgery. Their role is to widen the options available within a multidisciplinary, personalised treatment plan.

    An image-guided treatment may provide local tumour control, preserve organ function, reduce treatment burden or allow systemic therapy to continue. It may be appropriate when surgery is not feasible or indicated, or when a minimally invasive approach is preferable because of frailty, previous treatments or patient preference.

    For some patients, this can mean a shorter hospital stay and faster recovery and less disruption to daily life.

    Interventional Oncology can contribute throughout the cancer pathway. Its role begins with image-guided biopsy and tissue acquisition, providing material for diagnosis and molecular profiling. It extends to potentially curative or consolidative local treatment, management of oligometastatic or oligoprogressive disease, preservation of organ function, symptom control and palliation. Often its greatest value lies not in being used in isolation, but in being combined and appropriately sequenced with systemic therapy and other local treatments. In selected patients, local treatment can also control a limited site of disease while an effective systemic therapy is continued; in others, it can postpone the need to start or change systemic therapy, creating a systemic-treatment-free interval. This broader perspective is essential if precision cancer care is to encompass not only the tumour’s biological profile, but also its location, distribution and suitability for local treatment.

    Another developing field is the interaction with the immune system. Tumour ablation and intra-arterial therapies can modify the tumour microenvironment and induce immune responses. Whether this can be translated into a clinically meaningful synergy with immunotherapy is an important area of ongoing research.

    The question is therefore no longer whether Interventional Oncology has a role in cancer care, but whether European cancer systems are organised to use it appropriately.

    Access remains uneven. Availability may depend on geography, local expertise and whether an interventional oncologist is involved in multidisciplinary decision-making. Even an effective treatment cannot benefit patients if it is not considered when their clinical pathway is discussed.

    Image-guided cancer therapies should therefore be represented in tumour boards, clinical guidelines and cancer pathways, and Interventional Oncology should be included in multidisciplinary cancer education. Other cancer specialists do not need to become experts in interventional procedures, but they should know when these treatments may be relevant and when referral for specialist evaluation is appropriate.

    Expanding access must go hand in hand with training, standards and continuous quality improvement. We support this through:

    • the European Curriculum and Syllabus for Interventional Oncology,
    • EBIR-IO specialist certification,
    • IASIOS accreditation for Interventional Oncology services,
    • and the European Conference on Interventional Oncology (ECIO)

    There is also an issue of equity. Patients should not miss an appropriate treatment because image-guided therapies are unavailable locally or are not routinely discussed. Better referral networks, clearer pathways and greater awareness could reduce these differences.

    Quality assessment should reflect this patient-centred role. Technical success alone is not sufficient. Relevant outcomes include local tumour control, complications, symptom relief, preservation of organ function, quality of life and patient-reported outcomes, as well as whether treatment allows systemic therapy to continue or avoids or delays a more invasive intervention. Measuring these outcomes consistently would strengthen the evidence base, support comparison and continuous improvement across centres, and help multidisciplinary teams identify which patients are most likely to benefit.

    Closer collaboration between the European Cancer Organisation and CIRSE can support this integration. The aim is not to create another professional silo, but to ensure that multidisciplinary teams can consider the full range of treatment options.

    Interventional Oncology is part of cancer care across Europe. More consistent integration into education, workforce planning, quality programmes and multidisciplinary pathways would make its contribution more visible, more accessible and, most importantly, more useful to patients.

    Read more
  • Publication

    The European Cancer Institute: A New Vision for Europe's Fight Against Cancer

    October 2026


    How can Europe ensure that its investments in cancer research and care deliver lasting results? A new report from the European Cancer Organisation sets out a roadmap for a possible solution: creating a European Cancer Institute.

    Read more